The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior

Despite being overexpressed in different tumor entities, RIO kinases are hardly characterized in mammalian cells. We investigated the role of these atypical kinases in different cancer cells. Using isogenic colon-, breast- and lung cancer cell lines, we demonstrate that knockdown of RIOK1, but not of RIOK2 or RIOK3, strongly impairs proliferation and invasiveness in conventional and 3D culture systems. Interestingly, these effects were mainly observed in RAS mutant cancer cells. In contrast, growth of RAS wildtype Caco-2 and Bcr-Abl-driven K562 cells is not affected by RIOK1 knockdown, suggesting a specific requirement for RIOK1 in the context of oncogenic RAS signaling. Furthermore, we show that RIOK1 activates NF-κB signaling and promotes cell cycle progression. Using proteomics, we identified the pro-invasive proteins Metadherin and Stathmin1 to be regulated by RIOK1. Additionally, we demonstrate that RIOK1 promotes lung colonization in vivo and that RIOK1 is overexpressed in different subtypes of human lung- and breast cancer. Altogether, our data suggest RIOK1 as a potential therapeutic target, especially in RAS-driven cancers.

[1]  Xin Hu,et al.  Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients , 2015, Oncotarget.

[2]  K. Mechtler,et al.  Rio1 promotes rDNA stability and downregulates RNA polymerase I to ensure rDNA segregation , 2015, Nature Communications.

[3]  E. Hurt,et al.  Driving ribosome assembly. , 2010, Biochimica et biophysica acta.

[4]  C. Meisinger,et al.  ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types , 2016, Nature Communications.

[5]  M. Huber,et al.  Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors , 2005 .

[6]  Christoph H. Emmerich,et al.  The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system , 2013, The Biochemical journal.

[7]  T. Golub,et al.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.

[8]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[9]  Yibin Kang,et al.  The Endoplasmic Reticulum Acts as a Platform for Ubiquitylated Components of Nuclear Factor κB Signaling , 2013, Science Signaling.

[10]  B. Hemmings,et al.  Modulation of the enzymatic properties of protein phosphatase 2A catalytic subunit by the recombinant 65-kDa regulatory subunit PR65alpha. , 1997, European journal of biochemistry.

[11]  Matthias Mann,et al.  IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .

[12]  R. Beroukhim,et al.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. , 2013, Cancer cell.

[13]  Yusuke Nakamura,et al.  Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer , 2007, Molecular Cancer Therapeutics.

[14]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[15]  P. Boag,et al.  Investigating the Role of RIO Protein Kinases in Caenorhabditis elegans , 2015, PloS one.

[16]  E. Petricoin,et al.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.

[17]  M. Werner,et al.  Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer , 2015, International journal of cancer.

[18]  A. Harris,et al.  Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis , 2014, Oncogene.

[19]  R. Mattingly,et al.  Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors , 2010, Journal of Pharmacology and Experimental Therapeutics.

[20]  H. Takaki,et al.  RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune response. , 2015, Cell reports.

[21]  A. Wlodawer,et al.  Structure and activity of the atypical serine kinase Rio1 , 2005, The FEBS journal.

[22]  G. Evan,et al.  Studies on the interaction of the human c-myc protein with cell nuclei: p62c-myc as a member of a discrete subset of nuclear proteins , 1985, Cell.

[23]  W. Bandlow,et al.  RIO1, an extraordinary novel protein kinase , 2002, FEBS letters.

[24]  M. Huber,et al.  Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. , 2005, European journal of immunology.

[25]  A. Wlodawer,et al.  A Family Portrait of the RIO Kinases* , 2005, Journal of Biological Chemistry.

[26]  Monilola A. Olayioye,et al.  B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. , 2015, Cancer research.

[27]  Karina Silina,et al.  Characterisation of tumour-associated antigens in colon cancer , 2002, Cancer Immunology, Immunotherapy.

[28]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[29]  Christopher M. Fife,et al.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration , 2017, Oncogene.

[30]  A. Baldwin,et al.  IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity , 2014, Genes & cancer.

[31]  A. Wlodawer,et al.  The RIO kinases: an atypical protein kinase family required for ribosome biogenesis and cell cycle progression. , 2005, Biochimica et biophysica acta.

[32]  T. Kitamura,et al.  Plat-E: an efficient and stable system for transient packaging of retroviruses , 2000, Gene Therapy.

[33]  Xin Hu,et al.  The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. , 2016, Cancer letters.

[34]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[35]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[36]  U. Kutay,et al.  Nuclear export and cytoplasmic maturation of ribosomal subunits , 2007, FEBS letters.

[37]  M. Loda,et al.  Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. , 2017, Cancer discovery.

[38]  P. Gleizes,et al.  Late Cytoplasmic Maturation of the Small Ribosomal Subunit Requires RIO Proteins in Saccharomyces cerevisiae , 2003, Molecular and Cellular Biology.

[39]  Nils Blüthgen,et al.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.

[40]  C. Berens,et al.  A novel MCF-10A line allowing conditional oncogene expression in 3D culture , 2011, Cell Communication and Signaling.

[41]  W. Zagórski,et al.  Development of novel molecular probes of the Rio1 atypical protein kinase. , 2013, Biochimica et biophysica acta.

[42]  M. Boerries,et al.  Consistency of the Proteome in Primary Human Keratinocytes With Respect to Gender, Age, and Skin Localization* , 2013, Molecular & Cellular Proteomics.

[43]  P. Fisher,et al.  Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. , 2006, Cancer research.

[44]  Gong Yang,et al.  Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. , 2015, Cancer letters.

[45]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[46]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[47]  A. Roidl,et al.  Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progression , 2002, Molecular microbiology.

[48]  Annie Mougin,et al.  Human RioK3 is a novel component of cytoplasmic pre-40S pre-ribosomal particles , 2012, RNA biology.

[49]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[50]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[51]  S. Braun,et al.  Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors , 2013, Leukemia.

[52]  Z. Su,et al.  Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling , 2008, Oncogene.

[53]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[54]  John B. Thomas,et al.  A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma , 2013, PLoS genetics.

[55]  J. Downward.  RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? , 2015, Clinical Cancer Research.

[56]  E. Jaffe,et al.  Mutations in the JAK/STAT and RAS signaling pathways are common in Intestinal T-cell Lymphomas , 2016, Leukemia.

[57]  H. Gabra,et al.  The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration , 2010, Nucleic acids research.

[58]  T. Brummer,et al.  Expression pattern and first functional characterization of riok-1 in Caenorhabditis elegans. , 2014, Gene expression patterns : GEP.

[59]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[60]  D. Engelberg,et al.  How Do Protein Kinases Take a Selfie (Autophosphorylate)? , 2016, Trends in biochemical sciences.

[61]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[62]  P. Fisher,et al.  Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. , 2008, Cancer research.

[63]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[64]  Gary D Bader,et al.  The human genome and drug discovery after a decade. Roads (still) not taken , 2011, 1102.0448.

[65]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[66]  N. Koide,et al.  Astrocyte elevated gene‐1 (AEG‐1) is induced by lipopolysaccharide as toll‐like receptor 4 (TLR4) ligand and regulates TLR4 signalling , 2009, Immunology.

[67]  A. Sickmann,et al.  RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity* , 2010, The Journal of Biological Chemistry.

[68]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[69]  Ulrike Kutay,et al.  Distinct cytoplasmic maturation steps of 40S ribosomal subunit precursors require hRio2 , 2009, The Journal of cell biology.

[70]  R. Rad,et al.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.

[71]  Xin Wang,et al.  The role of MTDH/AEG-1 in the progression of cancer. , 2015, International journal of clinical and experimental medicine.

[72]  I. Kiburu,et al.  Interaction of Rio1 Kinase with Toyocamycin Reveals a Conformational Switch That Controls Oligomeric State and Catalytic Activity , 2012, PloS one.

[73]  Hong‐Lin Chen,et al.  High Expression of RIOK2 and NOB1 Predict Human Non-small Cell Lung Cancer Outcomes , 2016, Scientific Reports.

[74]  E. Petfalski,et al.  Rio1 mediates ATP-dependent final maturation of 40S ribosomal subunits , 2014, Nucleic acids research.

[75]  U. Rapp,et al.  Ras oncogenes and their downstream targets. , 2007, Biochimica et biophysica acta.

[76]  Ulrike Kutay,et al.  The kinase activity of human Rio1 is required for final steps of cytoplasmic maturation of 40S subunits , 2012, Molecular biology of the cell.

[77]  Damian Szklarczyk,et al.  STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..

[78]  D B Young,et al.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.

[79]  J. Tchinda,et al.  Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening , 2016, BMC Genomics.

[80]  P. Fisher,et al.  Activation of the Nuclear Factor κB Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis , 2006 .

[81]  T. Michoel,et al.  SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer , 2015, Molecular oncology.

[82]  M. Looso,et al.  Quantitative analysis of the TNF-α-induced phosphoproteome reveals AEG-1/MTDH/LYRIC as an IKKβ substrate , 2015, Nature Communications.

[83]  A. Kernytsky,et al.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. , 2016, Cell reports.

[84]  C. Der,et al.  Oncogenic Ha-Ras-induced Signaling Activates NF-κB Transcriptional Activity, Which Is Required for Cellular Transformation* , 1997, The Journal of Biological Chemistry.

[85]  Yinyin Yuan,et al.  Global Analysis of mRNA, Translation, and Protein Localization: Local Translation Is a Key Regulator of Cell Protrusions , 2015, Developmental cell.

[86]  Joel Greshock,et al.  High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. , 2016, Cancer research.

[87]  E. Hurt,et al.  Dominant Rio1 kinase/ATPase catalytic mutant induces trapping of late pre-40S biogenesis factors in 80S-like ribosomes , 2014, Nucleic acids research.

[88]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.